Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
| ▸ | VNN1 | O95497 | 5/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.49 |
| ▸ | KLK1 | P06870 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17237438 | 0.83 | NPC1 (0.67) | ROCK2ROCK1VNN1 | |
| SCHEMBL25044558 | 0.81 | L3MBTL1 (0.69) | ROCK2ROCK1KDM4E | |
| SCHEMBL3608476 | 0.80 | GRM5 (0.56) | VNN1 | |
| SCHEMBL9365904 | 0.79 | MAOA (0.66) | ROCK2ROCK1VNN1MAOAIDO1 | |
| SCHEMBL13491458 | 0.78 | ROCK2 (0.56) | ROCK2ROCK1VNN1MAOAIDO1 | |
| SCHEMBL30737520 | 0.77 | MAOA (0.57) | ROCK2ROCK1VNN1MAOAIDO1 | |
| SCHEMBL25374278 | 0.76 | POLB (0.57) | ROCK2VNN1MAOAKLKB1KLK1 | |
| SCHEMBL3461756 | 0.76 | ERCC1 (0.60) | ROCK2VNN1MAOAKLKB1KLK1 | |
| SCHEMBL11627692 | 0.76 | VNN1 (0.67) | ROCK2VNN1 | |
| SCHEMBL26507994 | 0.75 | ROCK2 (0.52) | ROCK2ROCK1VNN1MAOAKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482343-B2 | Compounds, methods and compositions | CYTOKINETICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070135432-A1 | Compounds, methods and compositions | CYTOKINETICS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-7166595-B2 | Compounds, methods and compositions | CYTOKINETICS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135432-A1 | Compounds, methods and compositions | ALPP, PCNA, MKI67 | ROCK2 1991/4885ROCK1 1781/4885VNN1 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.